Neko Health raises $700 million to expand AI body scans in the US

artificialintelligence-news.com Jul 16, 2026

Neko Health raises $700 million to expand AI body scans in the US

Curated by Shubham · TechCapsules · Jul 16, 2026

AI-summarised brief · reviewed before publication

Neko Health secured $700 million in a Series C funding round to expand its AI-driven preventive screening clinics into the United States, beginning with a location in New York. The round was led by Lightspeed Venture Partners and O.G. Venture Partners, with participation from existing investors like Atomico and General Catalyst, as well as new backers including Liberty City Ventures. High-profile individual investors such as Mark Zuckerberg, Priscilla Chan, and Maria Sharapova also contributed. This investment brings Neko’s total disclosed funding since 2023 to over $1 billion. The company’s service combines full-body scans, blood tests, and proprietary sensors to detect risks for conditions like skin cancer and cardiovascular disease. Neko currently operates eight clinics in the UK and Sweden, having completed 100,000 scans since 2023. The new capital will support US expansion and further research and development of its medical devices.

💡 Why It Matters

· The entry of celebrity-backed capital into direct-to-consumer preventive care signals a shift toward premium, convenience-driven health monitoring.
· This model challenges traditional healthcare by bundling disparate diagnostic tests into a single, subscription-style experience.

Read full article on artificialintelligence-news.com

China completes world’s first commercial brain-computer interface implant

China has successfully completed the world’s first commercial surgery involving an invasive brain-computer interface (BCI) device. The procedure took place at Huashan Hospital in Shanghai, where surgeons implanted the NEO device, developed by local start-up Neuracle Medical Technology, onto a patient suffering from hand mobility impairment due to a spinal cord injury sustained a decade ago. The coin-sized chip sits on the brain’s outer surface, capturing stable epidural signals to translate neural activity into hand movements. Approved by China’s National Medical Products Administration in March, the NEO became the first commercially prescribed BCI globally. Within four months of clearance, the device moved through production, hospital integration, and patient screening, eventually being included in local commercial health insurance. The patient recovered with stable vital signs, marking a significant milestone in neurotechnology and underscoring China’s competitive push against rivals like Elon Musk’s Neuralink in the global race for advanced medical implants.

💡 This rapid transition from regulatory approval to insured commercial use demonstrates a streamlined pathway for neurotech adoption that Western markets have yet to replicate. It establishes a tangible benchmark for how quickly invasive medical devices can reach patients, challenging the traditional multi-year lag between clinical trials and widespread market availability.

semiconductor-digest.com · Jul 16

The Invisible Wearable: New Skin Sensors Revolutionizing Health Monitoring

Researchers from the University of Tokyo and collaborating institutions have developed ultrathin, stretchable on-skin electrodes that are effectively invisible and undetectable by touch. Published in Science Advances, the study details these sensors, which measure biological signals like eye movements, facial muscle activity, and brain activity. The electrodes utilize a 200-nanometer elastic film and transparent conductive nanowires to match natural skin appearance and texture. This design eliminates the glossy look of conventional wearables, reducing appearance artifacts where visible devices alter user behavior or social interactions. Experiments confirmed that neither wearers nor observers could reliably detect the sensors. The technology provides signal quality superior to traditional gel electrodes due to lower skin impedance. Senior author Naoji Matsuhisa emphasizes that integrating electronics into daily life requires devices to disappear into the background. The sensors work across various skin tones and remain breathable. Potential applications include monitoring emotional states, cognitive function, and enabling new human-machine interaction methods through subtle facial expressions and eye movements, moving toward seamless technology integration.

💡 By eliminating the psychological burden of visible medical devices, this technology enables authentic behavioral data collection in social settings. It shifts health monitoring from a clinical intrusion to a seamless, background process that respects user privacy and natural social dynamics.

hitconsultant.net · Jul 16

XRHealth Acquires Swing Therapeutics to Create Largest Extended Reality Chronic Pain Platform

XRHealth has formally acquired Swing Therapeutics, establishing the largest multi-device extended reality digital health platform for chronic conditions. The transaction incorporates Swing’s flagship Stanza program, the first FDA De Novo–authorized prescription digital behavioral therapeutic for fibromyalgia symptoms affecting 10 million Americans. Validated by a Phase 3 randomized controlled trial published in The Lancet, Stanza utilizes Acceptance and Commitment Therapy to reduce pain, fatigue, and depression. The deal also integrates Swing Care, a virtual specialty clinic led by Dr. Andrea Chadwick, combining behavioral software with physician-monitored medication management. Operating on a fully covered model, the combined infrastructure deploys across VR glasses, smartphones, and wearables. It delivers continuous, personalized whole-patient care reimbursed via Medicare Part B, VA programs, and commercial insurance, shifting focus from consumer widgets to clinically validated, software-driven interventions.

💡 The acquisition validates a reimbursement-ready model for digital therapeutics, proving that immersive technology can generate sustainable revenue through established insurance pathways. By merging FDA-authorized software with active physician oversight, the platform transforms chronic pain management from passive self-care into a billable, clinically integrated medical service.

thequantuminsider.com · Jul 15

High Q Technologies Expands Quantum Protein Analysis Platform For Alzheimer’s Drug Discovery

High Q Technologies has expanded its quantum-enabled electron paramagnetic resonance (EPR) platform, Fathom, to enhance Alzheimer’s and neurodegenerative disease drug discovery. The system uses quantum sensors to capture multiple protein configurations simultaneously, offering deeper insights into protein behavior. The company partnered with Creative Biostructure to increase global access, supported by the Canadian government and the University of Waterloo’s quantum tech accelerator.

💡 By revealing dynamic protein movements that traditional methods miss, High Q’s technology could help researchers avoid costly dead ends in drug development. This partnership accelerates the application of quantum sensing in a field where most Alzheimer’s treatments fail in late-stage trials.

adaderana.lk · Jul 15

Humanoid robots perform live surgery in world first

Researchers from the University of California San Diego successfully conducted the world’s first live surgeries using teleoperated humanoid robots. Published in Nature, the study details two laparoscopic gallbladder removal procedures performed on pigs. In one trial, a single robot handled instruments while a human assisted; in the second, two robots collaborated under remote surgeon control. These five-foot machines utilized standard surgical tools within a human-sized operating room, copying surgeons’ movements without making independent medical decisions. The experiment served as a proof of concept, demonstrating that general-purpose humanoids can manipulate delicate tissue and place clips with sufficient precision. While the trial confirmed technical feasibility, it also identified challenges that must be resolved before human trials. This milestone distinguishes itself from previous robotic surgeries by employing mobile, general-purpose humanoids rather than fixed, bulky systems, potentially enabling remote surgical care in underserved areas.

💡 Mobile humanoids using standard tools bypass the infrastructure limits of fixed robotic arms, making remote surgery viable in resource-poor settings. This shift transforms surgical access from a location-dependent service to a remotely deliverable capability.

space.com · Jul 12

Space medicine breakthrough? Kidney and liver tissue bioprinted off Earth for 1st…

Auxilium Biotechnologies successfully bioprinted kidney and liver tissue aboard the International Space Station for the first time, utilizing its AMP-1 orbital bioprinter. The June experiments, which also produced cartilage and 28 nerve repair implants, returned to Earth via a SpaceX Dragon capsule on June 17. Using designs from the Wake Forest Institute for Regenerative Medicine, the mission demonstrated the ability to manufacture multiple tissue types in a single flight. CEO Jacob Koffler highlighted the technology’s versatility and scalability, while WFIRM director Anthony Atala noted that uniform cell distribution in microgravity offers real possibilities for medical device manufacturing. This achievement distinguishes Auxilium from previous ISS bioprinting efforts, such as the 2018 Russian cartilage experiment, by producing complex organs and implants simultaneously. Engineering VP Isac Lazarovits described the mission as a milestone toward routine in-space biomanufacturing, emphasizing the importance of collaboration and volume production for future commercial operations in orbit.

💡 This success proves that microgravity enables uniform cell distribution, a critical factor for creating functional, complex human organs that are difficult to manufacture on Earth. It validates space-based biomanufacturing as a viable pathway for producing high-quality regenerative medicine products.